Cyntellect announced this week the appointment of Tina Nova to the company’s board of directors. Nova is the president, CEO and co-founder of Genoptix. She also co-founded Nanogen, where she served as chief operating officer and president from 1994 to 2000. In addition, Nova served as chief operating officer of Selective Genetics from 1992-1994, and held various director-level positions with Ligand Pharmaceuticals from 1988 to 1992.
Beckman Coulter has named Scott Garrett as its CEO, effective Feb. 21, the company said last week. Garrett, who is currently president and chief operating officer, will replace current CEO John Wareham, who is retiring. Wareham will remain as chairman of the board until the annual shareholder meeting to be held April 7, Beckman Coulter said.
In addition, Garrett was elected to Beckman’s board of directors, effective Jan. 17, raising the number of directors to 12, the company said.
Garrett joined Beckman Coulter in 2002. He had previously served as CEO of Garrett Capital Advisors and Kendro Laboratory Products. He also has almost 20 years of experience with Baxter International/American Hospital Supply Corporation, Beckman said.
Illumina announced last week that William Rastetter has been named non-executive chairman of the company’s board of directors, and that John Stuelpnagel has been promoted to the newly-created position of chief operating officer.
Rastetter will continue full time as the executive chairman of Biogen. Prior to joining Biogen, Rastetter worked at Genentech from 1982 to 1986, and was previously an associated professor of chemistry at the Massachusetts Institute of Technology. Rastetter has been an Illumina board member since 1998.
Stuelpnagel was one of the founders of Illumina in 1998. Prior to being promoted to COO, Stuelpnagel was senior vice president of operations.